Mentions of cybersecurity increased in the pharmaceutical industry in Q1 2023
Notably, cybersecurity was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of environment and robotics, according to GlobalData.
Of the 50 leading companies in the pharmaceutical industry, Alnylam Pharmaceuticals had the greatest increase in references for cybersecurity in Q1 2023, compared with the previous quarter. GlobalData identified 21 cybersecurity-related sentences in the company’s filings – 5% of all sentences – and an increase of 100% in Q1 2023 compared with Q4 2022. Sarepta Therapeutics’s mentions of cybersecurity rose by 100% to 19 and Regeneron Pharmaceuticals’s by 100% to 15 and Horizon Therapeutics’s by 100% to 10 and Incyte’s by 100% to 9.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for cybersecurity in Q1 2023 was 100.
To further understand GlobalData’s analysis on Cybersecurity in Healthcare – Thematic Research market, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.
Source link
#Mentions #cybersecurity #increased #pharmaceutical #industry
